ESR1 and breast cancer: In summary, this US SEER study showed that Predict largely underestimated the 5-year cancer-specific mortality in women diagnosed with a second estrogen receptor–positive breast cancer and in some subgroups of women diagnosed with a second estrogen receptor–negative breast cancer.